2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Monday, October 22, 2018

9:00AM-11:00AM: Abstract Number: 1797

An Update on Pulmonary Artery Involvement in Behcet’s Syndrome: More Pulmonary Artery Thrombotic Disease and a Better Outcome

Vasculitis Poster II: Behҫet’s Disease and IgG4-Related Disease

9:00AM-11:00AM: Abstract Number: 1295

Anakinra Is More Effective at Reducing Pain from Acute Crystal Induced Arthritis When Compared to Conventional Therapy: A Retrospective Review at a Tertiary Care Center

Metabolic and Crystal Arthropathies – Basic and Clinical Science Poster I

9:00AM-11:00AM: Abstract Number: 1324

Anakinra Treatment in Refractory Cases of Adult-Onset Still Disease: Case Series

Miscellaneous Rheumatic and Inflammatory Diseases Poster II: Interstitial Lung Disease, Still's Disease, FMF, Polychondritis

9:00AM-11:00AM: Abstract Number: 1815

Aneurysmal Lesions in Behcet’s Disease: A Report of 69 Cases from a Single Center

Vasculitis Poster II: Behҫet’s Disease and IgG4-Related Disease

9:00AM-11:00AM: Abstract Number: 1340

Anti-Aminoacyl-tRNA-Synthetase Antibodies Which Are Positive By ELISA but Negative By RNA-Immunoprecipitation Suggest Different Antigen Recognition and Clinical Relevance Different from Typical Anti-Synthetase Syndrome

Muscle Biology, Myositis and Myopathies Poster II: Basic and Translational Science

9:00AM-11:00AM: Abstract Number: 1551

Anti-Drug Antibodies to Certolizumab Pegol Are Assiciated with Low Drug Levels and Reduced Clinical Response at 3 Months in Patients with Inflammatory Joint Diseases

Rheumatoid Arthritis – Treatments Poster II: PROs, Safety and Comorbidity

9:00AM-11:00AM: Abstract Number: 1001

Anti-Fractalkine Monoclonal Antibody Dislodges Intravascular Monocytes Involved in Exacerbation of Synovial Inflammation in Collagen-Induced Arthritis Model

Cytokines and Cell Trafficking Poster

9:00AM-11:00AM: Abstract Number: 995

Anti-Fractalkine Monoclonal Antibody Inhibits Joint Destruction through Suppression of Osteoclast Precursor Migration and Induces Synovial Cell Death in Collagen-Induced Arthritis Model Mice

Cytokines and Cell Trafficking Poster

9:00AM-11:00AM: Abstract Number: 1521

Anti-IL-6 Therapy Modulates Leptin in Patients with Rheumatoid Arthritis

Rheumatoid Arthritis – Treatments Poster II: PROs, Safety and Comorbidity

9:00AM-11:00AM: Abstract Number: 1346

Anti-NT5c1A Autoantibodies As Biomarkers in Inclusion Body Myositis

Muscle Biology, Myositis and Myopathies Poster II: Basic and Translational Science

9:00AM-11:00AM: Abstract Number: 1344

Anti-Splicing Factor Proline/Glutamine-Richautoantibodies Rarely Co-Exist with Anti-Melanoma Differentiation-Associated Gene 5 Autoantibodies in a Cohort of Dermatomyositis Patients from the United States

Muscle Biology, Myositis and Myopathies Poster II: Basic and Translational Science

9:00AM-11:00AM: Abstract Number: 1219

Antibiotic Resistance Trends Among Bacteria Causing Septic Arthritis at One Medical Center between 2002-2016

Infection-related Rheumatic Disease Poster

9:00AM-11:00AM: Abstract Number: 1108

Antibody Repertoire Dynamics in Systemic Sclerosis after Myeloablative Autologous Hematopoietic Stem-Cell Transplantation or Cyclophosphamide Treatment

Systemic Sclerosis and Related Disorders – Basic Science Poster II

9:00AM-11:00AM: Abstract Number: 1691

Application of the Doris Algorithm for the Definition of Disease Remission and Its Relation with Damage Accrual over a 2-Year Period in a Cohort of Italian Patients with Systemic Lupus Erythematosus Classified According to Clinical Disease Patterns

Systemic Lupus Erythematosus – Clinical Poster II: Biomarkers and Outcomes

9:00AM-11:00AM: Abstract Number: 1379

Appraisal of the Educational Needs in Patients with Osteoarthritis Using the Educational Needs Assessment Tool Questionnaire

Osteoarthritis – Clinical Poster – ARHP

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].